Jean Jacques Bienaime - 14 Apr 2026 Form 4 Insider Report for Ascendis Pharma A/S (ASND)

Reporting relationship: Director
Issuer ticker: ASND
Reported as of: 14 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Sep 2026, 16:08:12 UTC
Prior SEC filing: 01 Apr 2026
Next SEC filing: 17 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael Wolff Jensen as attorney-in-fact for Jean J Bienaime

Key filing fact

Jean Jacques Bienaime filed Form 4 for Ascendis Pharma A/S (ASND) on 28 Sep 2026.

Key facts

This page summarizes Jean Jacques Bienaime's Form 4 filing for Ascendis Pharma A/S (ASND).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 28 Sep 2026, 16:08.

Change

Previous filing in this sequence was filed on 01 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001221590 Primary reporting owner

BIENAIME JEAN JACQUES

Relationship: Director
Address: C/O ASCENDIS PHARMA A/S, TUBORG BOULEVARD 12, HELLERUP, DENMARK
Signature: /s/ Michael Wolff Jensen as attorney-in-fact for Jean J Bienaime
Signature date: 28 Sep 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ASND transaction Derivative

Warrants

Disposed to Issuer

Transaction value
Shares: -9,160
Change %: -100%
Price
Shares after: 0
Date: 14 Apr 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 9,160
Exercise price: $172.35
Footnotes: F1, F2

ASND transaction Derivative

Warrants

Award

Transaction value
Shares: +9,160
Change %
Price
Shares after: 9,160
Date: 14 Apr 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 9,160
Exercise price: $249.84
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The warrants vest 25% on June 10, 2026 and thereafter in 36 equal monthly installments.

Footnote F2

The Reporting Person agreed to cancellation of a warrant granted on June 10, 2025, and was awarded a new warrant as part of his appointment to the board of directors of the issuer.

Footnote F3

The warrants vest 25% on April 14, 2027 and thereafter in 36 equal monthly installments.